Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Sitagliptin, a once-daily, orally active, competitive and fully reversible inhibitor of DPP-4, was, as first in its class, introduced to the market as Januvia™. Recently, the US FDA approved ...

Sitagliptin (Januvia; Merck), the only marketed DPP4 inhibitor, was approved in October 2006. As a monotherapy, sitagliptin dosed daily achieved HbA1c reductions similar to those seen with the ...

The latest verdict – in a federal appeals court – has upheld the validity of a key patent on sitagliptin, the active ingredient in Januvia, as well as metformin combinations Janumet and ...

Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

Januvia (sitagliptin) is a medication for type 2 diabetes. Along with diet and exercise, it can help lower blood sugar levels. Medicare Part D will generally cover prescription drugs, like Januvia.

Compared with their net prices prior to negotiation, negotiated prices for the 10 drugs ranged from 8% lower for dapagliflozin (Farxiga) to 42% lower for sitagliptin (Januvia), reported Olivier J.

Meanwhile Steglujan (ertugliflozin+sitagliptin), a fixed dose combination combining the SGLT2 with Merck’s Januvia, is approved in type 2 disease when patients who need both drugs. Ertugliflozin ...